AstraZeneca's Forxiga Recommended for EU Approval for Symptomatic Chronic Heart Failure
December 19 2022 - 2:46AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Monday that its Forxiga drug has been
recommended for approval in the European Union for certain types of
heart failure.
The recommendation covers heart failure with reduced ejection
fraction--a measure of the amount of blood the heart's left
ventricle pumps with each heartbeat.
The Anglo-Swedish pharma giant said the Committee for Medicinal
Products for Human Use of the European Medicines Agency based its
opinion on results from the Deliver Phase 3 trial.
The company said that if approved Forxiga will be the first
heart-failure therapy indicated across the full ejection fraction
range with a proven mortality reduction.
"If approved for this new, broader indication for heart failure
with mildly reduced or preserved ejection fraction, more patients
will be able to benefit from this well-tolerated and
guideline-directed treatment," the company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
December 19, 2022 02:31 ET (07:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
